Loading...
•
Mar 31, 2025
MannKind Q1 2025 Earnings Report
Reported financial results for the first quarter 2025
Key Takeaways
MannKind Corporation reported strong financial results for the first quarter of 2025, with significant increases in total revenue, net income, and non-GAAP net income compared to the same period in the prior year. The company also made progress on key pipeline programs, including Afrezza for pediatric patients and MNKD-101.
Total revenues increased by 18% year-over-year to $78.4 million in Q1 2025.
Net income rose by 24% to $13.2 million in Q1 2025.
Non-GAAP net income increased by 43% to $21.6 million in Q1 2025.
The company expects to file an sBLA for Afrezza in pediatric patients in mid-2025 and is on track with enrollment for the MNKD-101 Phase 3 trial.
Revenue by Segment
Forward Guidance
MannKind expects to make significant progress on its pipeline in 2025, including regulatory submission for pediatric Afrezza and advancement of MNKD-101 and MNKD-201.
Positive Outlook
- Expect to submit sBLA for Afrezza in pediatric patients in mid-2025.
- MNKD-101 Phase 3 trial enrollment on track for interim analysis, with 85% of anticipated sites activated and 55 patients randomized.
- Expect to continue to next phase of global development for MNKD-201 in 2H 2025.
- Topline results from the full study pediatric data set for Afrezza expected in 2Q 2025.
- Label application to update initial Afrezza conversion dose submitted to FDA and under review.
Challenges Ahead
- No specific negative forward guidance points were mentioned in the report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...